Sentences with phrase «member of the oncology»

Julia has also mapped competitive landscapes with a focus on immuno - oncology and melanoma as a member of the Oncology Team within the TechAtlas division of RA Capital.

Rutgers Cancer Institute of New Jersey has partnered with top cancer centers across the nation to become a member of the Oncology Research Information Exchange Network (ORIEN).

I've also been a member of the Oncology Nutrition Dietetics Practice group for years.

For additional information regarding any of these oncology studies, please contact Ilene Kurzman or members of the Oncology Service at [phone].

Not exact matches

Professor Josep Tabernero, a member of the scientific committee for the EORTC - NCI - AACR Symposium and head of the medical oncology department at Vall d'Hebron University Hospital and director of the Vall d'Hebron Institute of Oncology, Barcelona, Spain, commented: «These are encouraging results, which show that galeterone has significant clinical activity in men with castration - resistant prostate cancer that fails to respond to otheoncology department at Vall d'Hebron University Hospital and director of the Vall d'Hebron Institute of Oncology, Barcelona, Spain, commented: «These are encouraging results, which show that galeterone has significant clinical activity in men with castration - resistant prostate cancer that fails to respond to otheOncology, Barcelona, Spain, commented: «These are encouraging results, which show that galeterone has significant clinical activity in men with castration - resistant prostate cancer that fails to respond to other drugs.

We have estimated that up to 15 percent of patients will be candidates for dose optimization,» explained senior study author Javier F.Torres - Roca, MD, director of Clinical Research and associate member of the Department of Radiation Oncology at Moffitt.

Garon is a member of the UCLA Jonsson Comprehensive Cancer and an associate clinical professor of hematology and oncology.

«Although FDA approval is critically important for introducing a new screening test or algorithm, providers ultimately rely on guidance or guidelines to help them make the best decisions for their patients and want to understand advantages, disadvantages and unknowns associated with a new screening approach,» said Huh, who is a senior scientist for the UAB Comprehensive Cancer Center, Director of the UAB Division of Gynecologic Oncology, and is also a board member for both the American Society for Colposcopy and Cervical Pathology and the Society of Gynecologic Oncology.

«Patients diagnosed with early - stage prostate cancer — and that's the vast majority of patients with this disease — face many treatment options that are thought to be similarly efficacious,» said Ronald C. Chen, MD, MPH, UNC Lineberger member and associate professor in the UNC School of Medicine Department of Radiation Oncology.

Other UT Southwestern faculty members who contributed to this research are: Dr. Boning Gao, Assistant Professor with the Hamon Center for Therapeutic Oncology Research and Pharmacology; Dr. Kimmo Hatanpaa, Associate Professor of Pathology; Dr. Kemp Kernstine, Professor of Cardiovascular and Thoracic Surgery and holder of the Robert Tucker Hayes Foundation Distinguished Chair in Cardiothoracic Surgery; Dr. Yang Xie, Associate Professor of Clinical Sciences and Bioinformatics; Dr. Hong Zhu, Assistant Professor of Clinical Sciences and with the Simmons Cancer Center; Dr. Farjana Fattah, Assistant Professor with the Simmons Cancer Center and Pathology; Dr. Masaya Takahashi, Associate Professor with the Advanced Imaging Research and Radiology; Dr. Bipasha Mukherjee, Assistant Professor of Radiation Oncology; Dr. Sandeep Burma, Associate Professor of Radiation Oncology; and Dr. Jonathan Dowell, Professor of Internal Medicine;

Young people with body mass indexes (BMIs) over 30 are more likely to experience aggressive malignancies, says author Nathan A. Berger, MD, Hanna - Payne Professor of Experimental Medicine; director of the Center for Science, Health and Society; member of the Case Comprehensive Cancer Center; and professor of medicine, biochemistry, oncology and genetics at Case Western Reserve University School of Medicine.

«This is a step forward in understanding pancreatic cancer's resistance to standard therapies,» said principal investigator Gregory Beatty, MD, PhD, an assistant professor of Hematology / Oncology at Penn and a member of Penn's Abramson Cancer Center.

«While tumor profiling holds the promise of improved therapeutics through personalized medicine, it is important that both clinicians and patients discuss the possibilities of incidental findings prior to ordering the testing, as the findings can have serious implications for both the patient and their family members,» said Melinda Yushak, M.D., M.P.H., first author on the study and a medical oncology fellow in Yale School of Medicine.

«While e-cigarettes may reduce smoking rates and attendant adverse health risks, we will not know for sure until these products are researched and regulated,» said Peter Paul Yu, president of the 35,000 - member American Society of Clinical Oncology, in a statement.

The study published today was done in collaboration with the labs headed by Salvador Aznar Benitah and Angel R. Nebreda, both members of IRB Barcelona's Oncology Programme, and with the labs led by Violeta Serra, at the Vall d'Hebrón Institute of Oncology (VHIO), Aleix Prat, at the Hospital Clínic de Barcelona, and Joan Albanell, at the Hospital del Mar..

«We found that pemetrexed combined with cisplatin is less toxic, well tolerated, and should be developed for further treatment of cervical cancer,» said gynecologic oncology specialist Dr. David Miller, Professor of Obstetrics and Gynecology and a member of the Harold C. Simmons Cancer Center.

The lab is also working with the Breast Oncology Program at UCSF to make this data part of an adaptive clinical trial called I - SPY, which lets researchers identify the most effective therapies based on patient molecular profiling, and is collaborating with members of the UCSF Institute for Computational Health Sciences (ICHS) to put these and other public data into a centralized database that clinicians can access through an app to help make the most appropriate treatment decisions.

In addition to monitoring the response of injected melanoma tumors, we are also measuring the boost in the anti-tumor immune cells of patients after injection,» explained Amod A. Sarnaik, M.D., assistant member of Moffitt's Cutaneous Oncology Program.

However, some of these cancers become resistant to the effects of radiation over time, according to Venu Raman, Ph.D., an associate professor of radiology and radiological science and of oncology at the Johns Hopkins University School of Medicine and member of the Johns Hopkins Kimmel Cancer Center.

«Even before the patient completes all of the MRIs, CT scans and other imaging procedures following diagnosis, we can have a recommendation for which drug and dosage to prescribe,» said Kareem Azab, PhD, an assistant professor of radiation oncology at the School of Medicine and the Siteman Cancer Center member who leads the research.

«Identification of these variations has helped the family to better understand why their children developed cancer and to plan for the future,» said co-author Kim Nichols, M.D., a member of the St. Jude Oncology department and director of the St. Jude Cancer Predisposition Division.

The study lasted two decades and was led by Dr. Mitchell Kamrava, an assistant professor of radiation oncology at UCLA and member of the Jonsson Comprehensive Cancer Center.

SR I Dr Alexandru Grigorescu, medical oncology consultant at the Institute of Oncology Bucharest, Romania, member of the ESMO Palliative Care Working Group, said: «The integration of palliative care in oncology is a choncology consultant at the Institute of Oncology Bucharest, Romania, member of the ESMO Palliative Care Working Group, said: «The integration of palliative care in oncology is a chOncology Bucharest, Romania, member of the ESMO Palliative Care Working Group, said: «The integration of palliative care in oncology is a choncology is a challenge.

«ImmunoMap gives scientists a picture of the wide diversity of the immune system's responses to cellular antigens,» says Jonathan Schneck, M.D., Ph.D., professor of pathology, medicine and oncology at the Johns Hopkins University School of Medicine, and a member of the Johns Hopkins Kimmel Cancer Center.

Buettner, along with study senior authors Bryan Allen and Douglas Spitz, are faculty members at the University of Iowa's Department of Radiation Oncology, Free Radical and Radiation Biology Program, in the Holden Comprehensive Cancer Center.

«Until now, physicians have taken a «wait and see» approach to antiviral therapies following transplantation,» says Toor, a hematologist - oncologist in the Bone Marrow Transplant Program and member of the Developmental Therapeutics research program at VCU Massey Cancer Center as well as professor in the Division of Hematology, Oncology and Palliative Care at the VCU School of Medicine.

We were encouraged with the response,» said first and corresponding author Fariba Navid, M.D., an associate member of the St. Jude Department of Oncology.

This information can be used to further personalize cancer care based on patients» unique characteristics, and to find patients who may be prone to be intolerant of this standard type of treatment» said Mayer Fishman, M.D., Ph.D., senior member of Moffitt's Genitourinary Oncology Program.

That's given us the parts list,» said study co-senior author William Hahn, an institute member in the Broad Cancer Program, chief of the Division of Molecular and Cellular Oncology at Dana - Farber, and a leader in the Cancer Dependency Map initiative, a joint effort spanning the Broad Institute and Dana - Farber.

«One promising strategy to reduce the number of people affected by pancreatic cancer is to identify and treat premalignant pancreatic lesions,» said first author Jennifer Permuth - Wey, Ph.D., M.S., assistant member in the Departments of Cancer Epidemiology and Gastrointestinal Oncology at Moffitt.

«This study is a concrete step towards identifying which patients are more likely to experience these distressing symptoms,» said Mayer Fishman, M.D., Ph.D., senior member of Moffitt's Genitourinary Oncology Program.

She serves as an editorial board member of Molecular Cancer Research, Genome Research, and Molecular Oncology in addition to serving on the scientific advisory boards of Pacific Biosciences, DNA Nexus, and Edge Biosciences.

«To move the needle forward toward prolonged survival and better treatment outcomes, our research team created a combined investigational regimen for patients with locally advanced pancreatic cancer,» said Richard Tuli, MD, PhD, a radiation oncologist in the Department of Radiation Oncology and a member of the Samuel Oschin Comprehensive Cancer Institute.

He served as Chair of the Bioethics Committee of the Children's Oncology Group from 2002 - 2008, and was an appointed member of the Committee on Bioethics of the American Academy of Pediatrics from 1999 - 2005.

Family history of breast cancer continues to significantly increase chances of developing invasive breast tumors in women ages 65 and older, according to research published by a team led by Dejana Braithwaite, PhD, associate professor of oncology at Georgetown University School of Medicine and a member of Georgetown Lombardi Comprehensive Cancer Center.

«The early response is very promising, among the best that we have seen against neuroblastoma, but we still have a long way to go,» said first author Wayne Furman, M.D., a member of the St. Jude Department of Oncology.

«What we see is an association between shorter periods of progression - free survival and overall survival in patients whose blood has higher levels of hypermethylated DNA, and we can see this very early on, after just four weeks of treatment,» says Sara Sukumar, Ph.D., professor of oncology at the Johns Hopkins University School of Medicine and member of the Kimmel Cancer Center, who developed the test with Johns Hopkins scientist Mary Jo Fackler, Ph.D., and others.

She is a former member the editorial board of the Journal of Clinical Oncology, is currently on the editorial board of Cancer Research and the Breast Journal.

Our dedicated pediatric oncology team members have spent their careers specializing in care for all forms of childhood cancer, from the most common types of cancer to extremely rare childhood cancers.

Dr. Wolff is an Associate Professor of Oncology and member of the Breast Cancer Research Program at The Johns Hopkins Sidney Kimmel Comprehensive Cancer Center.

Associate Member, Departments of Pathology, Experimental Medicine, Oncology, Center for Host Resistance and Goodman Cancer Center, McGill University

Alongside his CEO role at Hookipa, Joern is Chairman of Molecular Partners AG and a Board member of Unum Therapeutics, both of which are developing next - gen immuno - oncology therapies.

Dr. Ehrlich serves as the Director of the Pediatric Trauma and is a member of the Solid Tumor Oncology Program at CS Mott Children's Hospital at the University of Michigan.

Dr Kapil Dhingra, associate editor of Annals of Oncology and managing member of KAPital Consulting LLC, USA, and author of the accompanying editorial in Annals of Oncology.

He is a Fellow of the American College of Physicians and a member of numerous scientific and medical organizations, including the American Association for the Advancement of Science, the American Society of Hematology, the American Society of Clinical Oncology, and the American Society for Blood and Marrow Transplantation.

She is a Fellow in the American College of Surgeons, and member of the Alameda - Contra Costa Medical Association, the East Bay Surgical Society, San Francisco Surgical Society, the American Society of Breast Surgeons, American Society of Breast Diseases, and the Society of Surgical Oncology.

He is a member of the High Risk Neurobalstoma Committee of COG, institutional performance review committee for COG Phase - I consortium and is the Principle Investigator of the Children's Oncology Group, Phase - I, Phase II - III Consortium studies at C.S. Mott Children's Hospital.

Dr. Richard Booton is Lead Lung Cancer Clinician & Chair, Thoracic Oncology Board, GM Clinical Lead for Lung Cancer Screening at Manchester Thoracic Oncology Centre and North West Lung Centre & University Hospital of South Manchester, Member of the BTOG Steering Committee, Chair of the IASLC Communications Committee and IASLC Regent for UK and Ireland.

With more than 15,000 members representing oncology professionals from over 130 countries worldwide, ESMO is the society of reference for oncology education and information.

He is a past president of the American Society of Pediatric Hematology / Oncology and is a member of the steering committee for Bone Tumors in the Children's Oncology Group.